NHS Extends Semaglutide Prescriptions to Over One Million Heart Disease Patients

<p>The National Institute for Health and Care Excellence (NICE) has recommended that semaglutide, the active compound marketed under the brand names Wegovy and Ozempic, be prescribed to more than one million adults living with cardiovascular disease on the NHS. The decision marks a significant expansion of the drug’s approved applications, extending its clinical use well beyond its established role in treating obesity and type 2 diabetes.</p>

<p>The recommendation is underpinned by a major randomised clinical trial involving 17,604 participants, which demonstrated that semaglutide reduces the risk of death from cardiovascular causes by 20 per cent. Critically, this protective effect was observed irrespective of the degree of weight loss achieved by patients, suggesting that the drug exerts a direct cardioprotective mechanism on the heart and blood vessels rather than operating solely through metabolic improvements linked to weight reduction.</p>

<p>Eligibility for the treatment will extend to approximately 1.2 million people who have previously experienced a heart attack or stroke, with prescriptions expected to become available from this summer. The drug will be offered as an adjunct to existing cardiovascular therapies, including statins, and will be accessible to patients with a Body Mass Index of 27 or above. A BMI of 27 represents the current UK average and is classified as marginally overweight rather than clinically obese, a threshold that substantially broadens the eligible patient population compared to prior NHS criteria.</p>

<p>Until this guidance, the NHS rollout of Wegovy had been restricted to approximately 50,000 individuals classified as severely obese. The updated recommendation from NICE represents, by any measure, a wholesale repositioning of GLP-1 receptor agonists within the NHS treatment framework, as it constitutes the first instance of this class of drug being recommended for a condition other than obesity or diabetes.</p>

<p>NHS England confirmed that it has negotiated a pricing agreement with Novo Nordisk, the Danish pharmaceutical group that manufactures semaglutide, to ensure the treatment meets the cost-effectiveness thresholds required for routine commissioning across the health service. NICE stated that, when deployed for the secondary prevention of heart attacks and strokes, semaglutide “provides benefits and value for money, so it can be used routinely across the NHS.”</p>

<p>Helen Williams, National Clinical Director for Cardiovascular Disease Prevention at NHS England, described the development as potentially life-changing for a patient cohort already at elevated risk of recurrent cardiovascular events. Williams noted that the treatment, when used in conjunction with a healthy diet and regular physical activity, could prevent thousands of future major cardiovascular incidents.</p>

<p>Helen Knight, Director of Medicines Evaluation at NICE, emphasised the strength of the clinical evidence, stating that trial participants taking semaglutide alongside existing heart medications were significantly less likely to suffer a subsequent heart attack or stroke. The clinical case for the intervention is contextualised by the scale of the broader public health challenge: over eight million people in the UK are currently living with heart and circulatory conditions, which collectively account for approximately a quarter of all deaths annually, equating to roughly 170,000 fatalities per year.</p>

<p>Dr Sonya Babu-Narayan, Clinical Director at the British Heart Foundation, welcomed the guidance, asserting that semaglutide and similar agents have now firmly established themselves as medicines with benefits extending beyond weight reduction. Juliet Bouverie, Chief Executive of the Stroke Association, echoed this sentiment, highlighting particular relevance for stroke survivors, many of whom face physical disabilities that limit mobility and complicate conventional weight management strategies.</p>

<p>The decision carries considerable implications for investors with exposure to Novo Nordisk and the broader GLP-1 therapeutics sector. The NHS endorsement for a cardiovascular indication not only validates the investment thesis around semaglutide’s long-term commercial potential but also signals a likely intensification of competition among pharmaceutical groups developing rival compounds in this space. The scale of the eligible population, combined with a negotiated NHS pricing structure, may constrain near-term revenue upside; however, the precedent set by securing a cardiovascular indication on a major public health system is a materially positive signal for the long-term addressable market of this drug class.</p>